Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
ENVVENO MEDICAL CORP (NVNO)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
$6.97-0.43%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for NVNO yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Progress in Transcatheter Venous Valve Endoprosthesis (TAVVE) pivotal study | enVVeno has a new patent that helps its key valve study. | Improving | Pivotal study progress stalls or FDA approval is delayed beyond 2026-Q3 | Qualitative: FDA IDE favorable (Apr 2026), Patent granted (Jul 2026) FDA granted favorable IDE decision for TAVVE pivotal study; U.S. patent received for venous valve system. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, loss-making medical-device business with a clinical-development catalyst, not an established durable compounder. The long-term thesis weakened this week, and confidence in the assessment is low.
The evidence does not provide a valuation measure or a clear account of what the market already assumes, so whether NVNO is cheap, fair, or expensive versus peers cannot be assessed. The muted share-price response to recent events does not establish what expectations are priced in.
Over the multi-year view, progress depends on advancing the TAVVE pivotal study and managing losses. Operating losses and cash burn improved between 2024-Q4 and 2026-Q1, but management remains behind on this priority, and the latest reported cash and investments balance has no subsequent update. Near term, erratic earnings and elevated miss risk keep execution uncertain, despite an April earnings beat and an earlier miss.
The thesis hinges on progress in the pivotal study, continued loss and cash-burn management, and whether the company can maintain enough cash to support operations. Near term, a guidance cut or further weakness in jobs data would add pressure, while continued strong results and guidance from healthcare bellwethers could support the sector backdrop.
For the next 1 to 3 years, NVNO remains a fragile, high-risk development story with limited evidence of consistent financial improvement. Its long-term thesis depends on clinical progress and better control of losses and cash needs. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A primary condition in ENVVENO MEDICAL CORP's published investment case. The stated target is Revenue approximately $25 million by 2026-09-30. |
| Broken |
| Revenue falls significantly below $25 million by 2026-Q3 |
Revenue: $0 FY2026-Q3; GAAP. Published target: Revenue approximately $25 million by 2026-09-30. Same fiscal period as the stored target. Oct 29, 20260 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Maintain cash and investments to support operations | Cash reserves of $28 million support ongoing work. | Intact | Cash and investments fall below $28 million | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextNewly stated in 2026-Q1. The company reported a cash and investments balance of approximately $28 million as of December 31, 2025. No subsequent updates on cash balances are provided, so the priority is stated but delivery on maintaining or growing cash reserves is not yet measurable. Delivery assessment Jul 28, 2026 |
Reduce operating losses and cash flow burn | Operating losses and cash burn have improved recently. | Under Pressure | Operating losses or cash burn worsen beyond 2026-Q1 levels | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated as a priority in 8 of last 8 quarters. Operating losses improved from negative $6.70M in 2024-Q4 to negative $4.06M in 2026-Q1, and cash flow burn improved from negative $5.11M to negative $3.24M over the same period. The trajectory shows limited progress in reducing losses and cash burn but consistent focus on managing these operational challenges. Delivery assessment Jul 28, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-6.22 → $-6.22 · observed estimates
$0.00B → $0.02B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-6.22 | $0 | 1 / 1 |
| 2026-07-25 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-07-26 | $-6.22 | $0 | 1 / 1 |
| 2026-07-27 | $-6.22 | $0 | 1 / 1 |
| 2026-07-28 | $-6.22 | $0 | 1 / 1 |
| 2026-07-29 | $-6.22 | $0 | 1 / 1 |
| 2026-07-30 | $-6.22 | $0 | 1 / 1 |
| 2026-07-31 | $-6.22 | $0 | 1 / 1 |
| 2026-08-01 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-08-02 | $-6.22 | $0 | 1 / 1 |
| 2026-08-03 | $-6.22 | $0 | 1 / 1 |
| 2026-08-04 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-08-05 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-08-06 | $-6.22 | $0 | 1 / 1 |
| 2026-08-07 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-08-08 | $-6.22 | $0 | 1 / 1 |
| 2026-08-09 | $-6.22 | $0 | 1 / 1 |
| 2026-08-10 | $-6.22 | $0 | 1 / 1 |
| 2026-08-12 | $-6.22 | $0 | 1 / 1 |
| 2026-08-13 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-08-14 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-08-15 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-08-16 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-08-17 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-08-18 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-08-19 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-08-20 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-08-21 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-08-22 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-08-23 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-08-24 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-08-25 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-08-26 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-08-27 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-08-28 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-08-29 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-08-30 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-08-31 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-09-01 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-09-02 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-09-03 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-09-04 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-09-05 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-09-06 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-09-07 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-09-08 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-09-09 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-09-10 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-09-11 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-09-12 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-09-13 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-09-14 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-09-15 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-09-16 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-09-17 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-09-18 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-09-19 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-09-20 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-09-21 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-09-22 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-09-23 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-09-24 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-09-25 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-09-26 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-09-27 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-09-28 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-09-29 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-09-30 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-10-01 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-10-02 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-10-03 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-10-04 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-10-05 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-10-06 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-10-07 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-10-08 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-10-09 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-10-10 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-10-11 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-10-12 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-10-13 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-10-14 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-10-15 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-10-16 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-10-17 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-10-18 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-10-19 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-10-20 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-10-21 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-10-22 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-10-23 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-10-24 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-10-25 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-10-26 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-10-27 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-10-28 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-10-29 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-10-30 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-10-31 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-11-01 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-11-02 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-11-03 | $-6.22 | $16,800,000 | 1 / 1 |
| 2026-11-04 | $-6.22 | $16,800,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 1 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.